Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07016620 · ClinicalTrials.gov registry record
Laser Ablation a Salvage Treatment for Obstructive Benign Prostatic Hyperplasia
A clinical trial of Benign Prostatic Hyperplasia (BPH), sponsored by The Cleveland Clinic.
- Recruiting
- Registry status
- 20
- Enrollment target
- 1
- Study location
NCT07016620: Recruiting study of Benign Prostatic Hyperplasia (BPH), sponsored by The Cleveland Clinic.
NCT07016620 is a study of Benign Prostatic Hyperplasia (BPH) that is actively recruiting participants, run by The Cleveland Clinic. The registered enrollment target is 20 participants, below the 107-participant average among 3 other Benign Prostatic Hyperplasia (BPH) trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07016620, a study of Benign Prostatic Hyperplasia (BPH), is actively recruiting participants, sponsored by The Cleveland Clinic.
- RECRUITING
- Registry status
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Benign prostatic hyperplasia (BPH) is a common condition affecting aging men, often leading to lower urinary tract symptoms (LUTS). While Minimally Invasive Surgical Therapies (MIST) procedures offer less invasive alternatives to traditional surgery, some patients experience symptom recurrence or require further intervention due to lack of adequate relief of obstruction. Treatment of persistent obstruction after MIST therapy (BPH salvage therapy) typically requires surgical intervention like transurethral resection of prostate (TURP). This study proposes to evaluate the effectiveness of in-office transperineal laser ablation (TPLA) using the Echolaser system as a minimally invasive treatment option for these patients, potentially avoiding more invasive surgical procedures. The Cleveland Clinic sees a high volume of BPH salvage patients, making this an ideal setting for this research.
Primary Outcome
Change in Urinary Function as measured with IPSS score, Uroflow variables (Qmax) and Post void residue (PVR)
Conditions Studied
Interventions
- PROCEDURE Transperineal Laser Ablation (TPLA)
Study Locations (1)
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-01-12 |
| Est. Completion | 2027-09-01 |
What NCT07016620 shows while recruiting
NCT07016620 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 107-participant average among 3 other Benign Prostatic Hyperplasia (BPH) trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Benign Prostatic Hyperplasia (BPH) appearing as the primary indexed condition, and to 1 intervention - of which Transperineal Laser Ablation (TPLA) is the first listed.
NCT07016620 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT07016620 about?
NCT07016620 is a clinical study titled "Laser Ablation a Salvage Treatment for Obstructive Benign Prostatic Hyperplasia". Benign prostatic hyperplasia (BPH) is a common condition affecting aging men, often leading to lower urinary tract symptoms (LUTS). While Minimally Invasive Surgical Therapies (MIST) procedures offer less invasive alternatives to traditional surgery, some patients experience symptom recurrence or re...
What is the current status of trial NCT07016620?
This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2026-01-12. Estimated completion is 2027-09-01.
What conditions does trial NCT07016620 study?
This clinical trial studies the following conditions: Benign Prostatic Hyperplasia (BPH).
What interventions are being tested in trial NCT07016620?
The interventions under investigation include: Transperineal Laser Ablation (TPLA) (PROCEDURE).
Who is sponsoring clinical trial NCT07016620?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07016620 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Benign Prostatic Hyperplasia (BPH)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI